Experimental Antiplatelet Drug CG-0255 Shows Advantages over Clopidogrel

Need an Account?

Content is available to registered users only. Registration is free.

Register now, or if you’ve already registered, log in.
News

Experimental Antiplatelet Drug CG-0255 Shows Advantages over Clopidogrel – Phase I Trial

Posted: 11/12/2023
Author:
Jason Wermers, CRTonline.org
Coronary News Articles Antiplatelet Therapy Bleeding Complications Cardiovascular Pharmacology 2023 AHA Late-Breaking Trials Technology & Regulatory

PHILADELPHIA – The experimental antiplatelet drug compound CG-0255 demonstrated several advantages over clopidogrel and was well-tolerated by patients, according to new phase I trial results.

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Need an Account?

News

Experimental Antiplatelet Drug CG-0255 Shows Advantages over Clopidogrel – Phase I Trial

Most Viewed Pages

Explore the Site

Stay Connected